# A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

> **NCT05630846** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 801 (actual)

## Conditions studied

- Measles; Mumps; Rubella; Chickenpox
- Measles

## Interventions

- **BIOLOGICAL:** Investigational MMRV(H)NS vaccine
- **BIOLOGICAL:** Investigational MM(H)RVNS vaccine
- **BIOLOGICAL:** Investigational M(L)M(L)R(L)V(L)NS vaccine
- **BIOLOGICAL:** Marketed MMRV_Lot 1 and Lot 2 vaccine

## Key facts

- **NCT ID:** NCT05630846
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-14
- **Primary completion:** 2024-06-07
- **Final completion:** 2024-10-14
- **Target enrollment:** 801 (ACTUAL)
- **Last updated:** 2025-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05630846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05630846, "A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05630846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*